Prevalence of diabetes in patients of Schizophrenia on long-term use of olanzapine

BACKGROUND-: Second generation antipsychotics such as olanzapine, are associated with a 5-fold increase in metabolic syndrome after three years of treatment AIM-: To study the prevalence of diabetes in patients of Schizophrenia on long term use of Olanzapine MATERIAL METHODS-: This study included patients diagnosed with schizophrenia. Data on a number of known and hypothesized risk factors for Type2 diabetes mellitus were collected. Longitudinal follow up study STUDY POPULATION-: All patients of schizophrenia coming for follow up Tests performed- Fasting Blood Glucose, Post-meal blood Glucose, HBA1c RESULT-: olanzapine (hazard ratio (HR) = 1.64, 95% confidence interval (CI): 1.22, 2.19) CONCLUSION-: Assuming that the observed associations are causal, approximately one third of new cases of diabetes may be attributed to use of olanzapine in patients taking these medications. Prescribers should be mindful of diabetes risks when treating patients with schizophrenia.